Comparability strategy and demonstration for post-approval production cell line change of a bevacizumab biosimilar IBI305
{{output}}
High-producing cell line could improve the affordability and availability of biotherapeutic products. A post-approval production cell line change, low-titer CHO-K1S to high-titer CHO-K1SV GS-KO, was performed for a China marketed bevacizumab biosimilar IBI305.... ...
